Evaluation of Effect of Weekend Admission on the Prevalence of Hospital-Acquired Conditions in Patients Receiving Cervical Fusions

World Neurosurgery
Timothy WenFrank L Acosta

Abstract

Hospital-acquired conditions (HACs) are defined by the Centers for Medicaid and Medicare Services (CMS) as preventable adverse events that do not qualify for reimbursement of resulting hospital costs. HACs have been employed as a metric for quality of patient care. Patients undergoing cervical spine fusions are at risk for occurrence of HACs because of limited mobility and potential extended hospital length of stay (LOS). Previous studies have not evaluated the contribution of weekend admission on the rate of HACs in this patient population. We abstracted data from the Nationwide Inpatient Sample to evaluate rate of HACs as a function of weekend admission among patients admitted for cervical fusions. Patients undergoing anterior and posterior cervical fusions were identified from the 2002-2010 Nationwide Inpatient Sample database. HACs as defined by the CMS were collected via International Classification of Diseases, Ninth Revision, Clinical Modification codes. Multivariate analysis, including adjustment for demographics, disease severity, admission acuity, and admission source, was used to evaluate the effect of weekend admission on HAC occurrence, prolonged LOS, and higher inpatient costs. During the period 2002-2010, 1,404,1...Continue Reading

References

Dec 22, 1998·Medical Care·C Czaplinski, D Diers
Sep 8, 2001·The New England Journal of Medicine·C M Bell, D A Redelmeier
Oct 9, 2003·JAMA : the Journal of the American Medical Association·Chunliu Zhan, Marlene R Miller
Jul 28, 2004·The American Journal of Medicine·Peter CramGary E Rosenthal
Mar 1, 2006·Critical Care Medicine·Derek C AngusUNKNOWN Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS)
Jul 26, 2006·European Journal of Internal Medicine·R BarbaA Zapatero
Mar 10, 2007·Stroke; a Journal of Cerebral Circulation·Gustavo SaposnikVladimir Hachinski
Mar 16, 2007·The New England Journal of Medicine·William J KostisUNKNOWN Myocardial Infarction Data Acquisition System (MIDAS 10) Study Group
Oct 9, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Deborah S YokoeDavid Classen
Oct 9, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Evelyn LoDeborah S Yokoe
Oct 14, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Abdel Aziz M ShaheenRobert P Myers
Feb 11, 2009·Circulation·Drahomir AujeskySaid A Ibrahim
May 23, 2009·Stroke; a Journal of Cerebral Circulation·R Webster CrowleyAaron S Dumont
Sep 10, 2009·Health Affairs·Peter D McNairAndrew B Bindman
Jul 14, 2010·Journal of Vascular Surgery·Teviah SachsMarc Schermerhorn
Mar 15, 2011·Journal of the American College of Surgeons·Dante M ConleyAtul A Gawande
Jul 29, 2011·Journal of Public Health·E M BurnsO D Faiz
Aug 19, 2011·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Michael A HorstAngela S Gambler
Nov 15, 2011·The Journal of Urology·Richard K Babayan
Apr 7, 2012·The American Journal of Cardiology·Abhishek DeshmukhJawahar L Mehta
Dec 19, 2012·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Veerasathpurush AllareddyMin Kyeong Lee
Apr 18, 2013·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Min Kyeong LeeVeerasathpurush Allareddy
Jun 5, 2013·The Laryngoscope·Amit KochharChristine G Gourin
Jun 18, 2014·Surgical Endoscopy·Anne O LidorMichael A Schweitzer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.